Neural Stem Cell Institute, Rensselaer NY

  • About Us
    • Our Mission
    • Our Team
  • Research
    • Alzheimer’s Program
    • Age-Related Macular Degeneration Program
    • Parkinson’s Disease Program
    • Spinal Cord Injury Program
    • Computing @ NSCI
  • NeuraCell
  • Tau Consortium
  • Press
  • Blog
  • Contact Us
    • Careers
    • Volunteer Internship
    • Collaboration Inquiries
    • Media Inquiries
  • Donate Now

 

    The Tau Consortium is a highly collaborative international group of investigators studying Tauopathies, which are neurodegenerative diseases like Alzheimer’s Disease, in which a protein called Tau misfolds and accumulates in the brain.  The Tau Consortium is funded by the Rainwater Charitable Foundation and is made up of scientists and clinicians working to understand what leads to Tauopathies and to develop treatments and ultimately cure these disorders.  The Stem Cell Group of the Tau Consortium consists of investigators from the University of California, Harvard, Washington University and Mount Sinai, New York, who are focused on developing  “disease in a dish” models to answer questions related to disease mechanism.  One key resource from this work is a world-class collection of induced pluripotent stem cells (iPSCs) generated from blood samples or small skin biopsies donated by patients carrying mutations linked to tauopathies or by healthy individuals. Currently, the iPSC collection includes seven different MAPT mutations and lines from several donors with progressive supranuclear palsy (PSP). Our goal is to continue to expand the collection each year with new and interesting mutations that will add to the research enterprise. Work is underway to create corrected isogenic controls for several of these lines. In addition, we plan to include de novo MAPT mutations introduced into normal, healthy control lines.

     The MAPT iPSC collections are now available to investigators in both for-profit and non-profit organizations. Please use the links below for more information about the collections, and the documentation process required to obtain these lines. Our recent publication on the cell lines is also available below.

https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(19)30335-2

Karch et al., A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies, Stem Cell Reports (2019), https://doi.org/10.1016/j.stemcr.2019.09.006

 

Process for Requesting Lines

All requests will be reviewed by the Tau Consortium’s Stem Cell Group. Typical request turn around time is 10 Business days, barring any delays from MTA execution, communication with PIs, and special requests that require an additional scope of work. Please submit the following:

  • Tau Consortium Induced Pluripotent Stem Cell Request Form [Download Form]
  • CV/Biosketch
  • Research summary: specific aims, background, preliminary data, sample size justification

         Upon approval, the required material transfer agreements must be signed prior to distribution. Please follow this link for more about on the collection’s scope, aim and additional information on the procedures for obtaining lines.

  • UBMTA Implementing Letter [ Download Doc ]
  • UBMTA Master Agreement [ Download Doc ]

Contact: Cindy Butler [ cindybutler@neuralsci.org ] Cost: Please contact us for pricing.

 

   Click here for the:

 Dermal Fibroblast Bank to Model Tauopathies

 

Click here for the:

Tau Consortium iPSC Line Collection

 

Click here for the:

Tau Consortium CRISPR/Cas9-Edited iPSC Line Collection

 

 

 

 

Stem Cells in the News

Neural Stem Cell Institute receives $300,000 grant for Research on Potential Cure for Macular Degeneration. Troy Record

Upcoming Events

September 30, 2016 5th Stem Cell Soiree Read More 

Blog

NSCI Female Scientists Inspiring Girls in Science!

September 7, 2018

Alima Ahmed, Student Volunteer at NSCI Wins Prestigious Award

August 27, 2018

Regenerative Eye Research- More Than Meets the Eye

June 8, 2018

Our Unique Organization

The Neural Stem Cell Institute (NSCI) is dedicated to developing regenerative stem cell therapies for various diseases of the central nervous system (CNS): the brain, spinal cord and retina, regardless of the cause of injury. Led by MacArthur “Genius” Award winner Dr. Sally Temple who helped discover and define nervous system stem cells, NSCI is the first independent, non-profit stem cell research institute in the USA.

Read More

Location

Neural Stem Cell Institute
One Discovery Drive
Rensselaer, NY 12144

Phone: (518) 694-8188
Fax: (518) 694-8187

Connect

  • Facebook
  • Twitter
  • YouTube